ClinicalTrials.gg
RecruitingNCT06482905Updated Mar 24, 2026

Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.

A Phase 1 interventional study of Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103 in High-grade Glioma and WHO Grade Ⅳ Glioma, sponsored by Tcelltech Inc.. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by Tcelltech Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 851 studies in Glioma with a site in United States — 142 open to participants now, 229 under way, 6 of them phase 3. Glioma · United States.

Planned enrollment
215th of 737
52 · median 30
Started
2024
with 31 others
Phase 1
338 of 851
63 open now
Primary completion
2026-09
later than 43 of 228 live
Registered
780th of 851
by date

Among the 851 studies in Glioma with a site in United States, this one is the 215th largest by planned enrollment of the 737 interventional ones that give a count, is one of 32 that started in 2024, is one of 338 in phase 1, reaches primary completion later than 43 of the 228 other live ones, and was the 780th registered.

Glioma

1,453 studies on the registry are indexed under Glioma; 349 are open to participants now.

Browse Glioma studies →

Open to participants now

142 of the 851 studies in Glioma with a site in United States are open now. Recruiting first, the newest first:

137 more — sign in →

All 142 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 56 (21%) stop at 75 or younger; 62 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 851 studies in Glioma with a site in United States, or all of them as a file.
02

Study summary

This is a phase I, open-Label, single/multiple dose, dose-escalation study to evaluate the safety, tolerability and antitumor activity of anti-B7-H3 CAR-T cell injection (TX103) in subjects with recurrent or progressive Grade 4 Glioma.The study also plan to explore the Maximum Tolerated Dose (MTD) and determine the Recommended Phase II Dose (RP2D) of the CAR-T cell therapy.

Read the detailed description

Eligible subjects will be enrolled into two sequential dose-escalating cohorts (i.e., A and B), and will be administrated TX103. Cohort A will receive TX103 exclusively through intraventricular (ICV) delivery, while cohort B will undergo dual intracavitary (ICT) and ICV delivery. Patients in each individual cohort will receive two TX103 infusions on Day 1 and 8 respectively, followed by a 14-day observation period in a 21-day treatment cycle.

Three escalating dosage levels are planned for each cohort. Both Cohorts A and B will adopt the traditional 3+3 dose escalation design with each dose level enrolled with 3 to 6 patients. The starting dose will be 6 × 10\^7 CAR+ T cells (i.e., Dose Level 1, DL1). Dose limiting toxicities (DLTs) will be assessed during the first cycle .

03

Conditions studied

  • High-grade Glioma
  • WHO Grade Ⅳ Glioma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must voluntarily participate in the study and sign a written document; subjects should be willing and able to follow and complete study procedures.
  2. Male or female subjects aged 18 to 75 years (both inclusive).
  3. Subject must have diagnosed grade 4 glioma, such as glioblastoma, grade 4 astrocytoma, diffuse hemispheric glioma, according to 2021 WHO Classification of Tumors of the CNS. Subjects must have had experienced disease recurrence or progression* after surgery combined with Stupp regimen (concurrent radiotherapy and temozolomide (TMZ) followed by adjuvant TMZ) and are not candidate for re-resection. For subjects harboring specific gene mutations, such as NTRK gene fusion or BRAF V600E mutation, they must have also progressed on corresponding mutation-directed therapies before enrollment.

    * Disease recurrence or progression must be confirmed by radiographic or histopathological diagnosis.

  4. Subjects with confirmed B7-H3 positive* (≥30%) tumor expression by immunohistochemistry (IHC) in either primary or recurrent tumor tissue.

    *B7-H3 positive rate is defined as the percentage of B7-H3 positive tumor cells in non-necrotic tumor tissue.

  5. Subjects with score of ≥60.
  6. Subjects should have adequate venous access for collection of peripheral blood mononuclear cells (PBMCs).
  7. Subjects with (LVEF) ≥ 40% within one month prior to the first dose.
  8. Subjects with oxygen saturation ≥95% under the resting state.
  9. Subjects with adequate organ function, as indicated by laboratory test results that meet the following criteria:

    • Hematological function: (ANC) ≥1.5×109/L, (Hb) ≥90g/L, count (PLT) ≥100×109/L, absolute lymphocytes count (ALC) ≥0.15×109/L. Blood transfusion, granulocyte (macrophage) colony stimulating factor, recombinant human erythropoietin, recombinant human thrombopoietin, platelet receptor agonist, recombinant human interleukin-11, and other supportive treatments are prohibited within 14 days before the test.
    • Liver function: Total (TBIL) ≤ 1.5 × , patients with Gilbert's syndrome (persistent or recurrent hyperbilirubinemia, presenting as unconjugated bilirubin in the absence of evidence of hemolysis or liver pathology) Except for elevated erythrocytes; (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN.
    • Renal function: serum creatinine (Scr) ≤1.5×ULN.
    • Coagulation function (in the absence of anticoagulant therapy): (PT) or activated partial thromboplastin time (APTT) or international normalized ratio (INR) ≤ 1.5×ULN.
    • Female subjects of must have a negative serum pregnancy test at screening and if a positive urine test or a negative result cannot be confirmed by urine test.
  10. Women of childbearing potential (which refer to women who have not been surgically sterilized and pre-menopausal women) should use highly effective and reliable method of (refer to Section 5.3 for contraception method) from the start of the study until 6 months after the last dose of the study drug; sexually active male subjects, if no vas deferens for ligation, consent must be given to the use of highly effective and reliable method of contraception from the start of the study until 6 months after the last dose of the study drug.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding female subjects.
  2. Subjects with viral infection during the screening period:

    • Serum antibody positive, treponema pallidum serology positive; OR
    • surface antigen (HBsAg) positive and peripheral blood HBV DNA test value exceeds the normal range; OR
    • virus (HCV) antibody positive and peripheral blood HCV RNA positive.
  3. Medical history and concomitant diseases:

    • Subjects who have received carmustine extended-release implantation surgery within 6 months;
    • Subjects with known or suspected active diseases, including but not limited to Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, etc.;
    • Subjects who are receiving systemic agents or subjects who need to use immunosuppressive agents for a long-time during treatment, except for intermittent topical, inhaled, or intranasal therapy;
    • Subjects with uncontrolled mental disorders, or who, in the Investigator's opinion, have a medical history or a history of mental states that may increase the risks associated with study participation or study drug administration, or that may interfere with the results;
    • The toxicity and side effects caused by previous treatment have not recovered to ≤ grade 1 (per 5.0); except for alopecia and other tolerable events judged by the Investigator;
    • Subjects who have participated in other interventional clinical studies within the past 1 month;
    • Subjects who have previously received CAR-T cell therapy or other gene therapy*;
    • Subjects with any serious or poorly controlled disease that, in the opinion of the Investigator, may increase the risk associated with study participation, study drug administration, or affect the subject's ability to receive study drug, including but not limited to cardiovascular and cerebrovascular diseases, renal insufficiency, pulmonary embolism, coagulopathy or requiring long-term anticoagulant therapy, active infection or uncontrollable infection requiring long-term systemic treatment;
    • Subjects with other malignant tumors in the past 3 years or at present, except for non-melanoma skin cancer, carcinoma in situ (such as cervix, bladder and breast cancer).
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Safety Run-In

    Single-dose administration of TX103 via intraventricular(ICV) or intracavitary (ICT) .

    Biological: Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103

  • Experimental
    Cohort A Single delivery route(Multi-dose)

    Administration of TX103 via intraventricular(ICV) on Days 1 and 8 in a 21-day treatment cycle.

    Biological: Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103

  • Experimental
    Cohort B Dual delivery route(Multi-dose)

    Administration of TX103 on Day 1 via intracavitary (ICT) and on Day 8 via intraventricular(ICV) in a 21-day treatment cycle.

    Biological: Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103

Interventions

  • BiologicalAnti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103

    Drug page: Chimeric Antigen Receptor T-cells

    Safety Run-In: Dose:6×10\^7 CAR+ T cells Cohort A Single delivery route(Multi-dose)、Cohort B Dual delivery route(Multi-dose): 3+3 dose escalation design: Dose Level 1: 6×10\^7 CAR+ T cells Dose Level 2: 1.5×10\^8 CAR+ T cells Dose Level 3: 2.5×10\^8 CAR+ T cells

06

What researchers measure

Primary outcomes

  1. Safety:Incidence of Dose Limiting Toxicity (DLT)

    Type, incidence, and severity of dose limiting toxicities (DLTs) within 28 days after the first TX103 infusion.

    Time frame: 28 days after the first TX103 infusion.

  2. Safety:Incidence and severity of adverse events (AEs)

    To evaluate the possible adverse events after TX103 infusion, including the incidence, and severity of AEs.

    Time frame: six months post CAR-T cells infusion.

Secondary outcomes

  1. Overall survival (OS)

    The proportion of subjects who have survived for more than 6 and12 months since the diagnosis of recurrent or progressive Grade 4 Glioma.

    Time frame: 6 and 12 months post CAR-T cells infusion.

  2. Post-relapse survival (PRS)

    The proportion of subjects who have survived for more than 6 and12 months since the diagnosis of recurrent or progressive Grade 4 Glioma.

    Time frame: 6 and 12 months post CAR-T cells infusion.

  3. Progression Free Survival (PFS)

    To evaluate the time from the start of TX103 therapy to disease progression (according to RANO2.0 criteria) or death from any cause, whichever occurs first. The proportion of progression-free subjects from the beginning of TX103 therapy to a fixed time point (6 months) after treatment (6-Mon PFS) will also be evaluated.

    Time frame: 1 year post CAR-T cells infusion.

  4. Disease Control Rate (DCR)

    To evaluate the proportion of subjects who achieved CR/PR/SD in the best overall response according to RANO2.0 criteria.

    Time frame: 1 year post CAR-T cells infusion.

  5. Duration of disease control (DDC)

    To evaluate the time from the first evaluation of tumor as CR, PR or SD to the first evaluation of PD or death from any cause.

    Time frame: 1 year post CAR-T cells infusion.

  6. Objective response rate (ORR)

    To evaluate the proportion of subjects who achieved CR/PR in the best response condition according to RANO2.0 criteria.

    Time frame: 1 year post CAR-T cells infusion.

  7. Time to Remission (TTR)

    To evaluate the time from the start of treatment to the first remission (CR/PR).

    Time frame: 1 year post CAR-T cells infusion.

  8. Duration of Response (DOR)

    DOR after TX103 infusion, defined as the time from the first evaluation of the tumor as CR or PR to the first evaluation of PD or death from any cause.

    Time frame: 1 year post CAR-T cells infusion.

  9. Neurological function evaluated by NANO scale

    Change in neurological function from baseline.

    Time frame: 1 year post CAR-T cells infusion.

  10. Quality of life score

    Change in Quality of life score from baseline.

    Time frame: 1 year post CAR-T cells infusion.

Other outcomes

  1. The immunogenicity of TX103

    Drug antibody (ADA) positive rate after infusion of TX103 cells.

    Time frame: up to 12 months.

  2. The positive rate of replication competent lentivirus tests

    Detect replication competent lentivirus (RCL).

    Time frame: up to 15 years.

  3. Incidence of Secondary Malignancies

    The frequency and occurrence of new, distinct cancerous growths that develop as a result of TX103.

    Time frame: up to 15 years.

  4. Peak Concentration (Cmax) of TX103 CAR gene

    Peak Concentration (Cmax) of TX103 CAR gene

    Time frame: Up to 12 months.

  5. Area under the concentration versus time curve (AUC) of TX103 CAR-T cells

    Area under the concentration versus time curve (AUC) of TX103 CAR-T cells

    Time frame: Up to 12 months.

  6. Peak concentration of cytokines

    Peak concentration of IL-2, IL-4,IL-6, IL-8,IL-10,IFN-γ, TNF-a

    Time frame: Up to 12 months.

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Sep 2026, 24 months after the start.

Of 47 industry-sponsored phase 1 interventional studies under Glioma, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 121. This study's planned 24 months is below that.

Counting every sponsor, half of 213 studies reached it within 59 months; a quarter within 36 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2024
First posted
Jul 1, 2024
StartActual
Sep 4, 2024
Primary completionEst.
Sep 2026
CompletionEst.
Jun 2027
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06482905
Lead sponsor
Tcelltech Inc.
Responsible party
Sponsor
First posted
Jul 1, 2024
Start date
Sep 4, 2024
Primary completion
Sep 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Mar 24, 2026

Study contacts

Rui Feng, MD
Contact
fengrui@tcelltech.com
+(86)13509312934
Xianzhen Chen, MM
Contact
chenxianzhen@tcelltech.com
+(86)18649725652
Gangxiong Huang, MD
study director · Tcelltech Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chimeric Antigen Receptor T-cells

Start the discussion